Hericium Erinaceus Mycelium and Probiotic of the Grape King Bio on Symptoms of Premenstrual Syndrome

NCT ID: NCT05443477

Last Updated: 2022-07-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

105 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-08

Study Completion Date

2023-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this experiment is to evaluate the efficacy of supplemental health food Grape King Hericium erinaceus Mycelium Capsules and Grape King Probiotic Capsules in improving physical and psychological symptoms, blood oxidative stress and inflammation indicators in women with premenstrual syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was a randomized, double-blinded and placebo-controlled research. This study was approved by the Institutional Review Board of the Chung Shan Medical University Hospital and all Participants signed the written informed consent to participate in the study.

Participants met the inclusion criteria, ie: age 20\~45 yr and a regular menstrual cycle (21\~35 days per cycle) were recruited through advertisements posted around the Chun Shan Medical university campus. In screening phase of this study, affective and one somatic symptom in before onset of menstruation in two consecutive cycles and was not affected by depression or anxiety disorder, she is examined by the Attending Physician of the Obstetrics and Gynecology Department to diagnosed a patient with premenstrual syndrome. In the intervention phase of this study, 105 eligible participant were randomly divided into intervention (Grape King Hericium erinaceus Mycelium Capsules and Grape King Probiotic Capsules) and control groups (n=35/group). Both subjects and researchers were blind to the treatment assignment until the statistical analysis was completed. All participants received two oral capsules containing Hericium erinaceus Mycelium, probiotics or placebo every day for the 3 months. The capsules of intervention supplementations and placebo provided by Grape King Biotechnology Inc in identical appearance and package to guarantee the blindness.

Data collection A validated semi-quantitative Food Frequency Questionnaire was used to obtain daily nutritional values of participants. To assess the symptoms of PMS, all subjects need to fill out daily record of severity of problems on a daily basis in the 3 months of intervention period and 6 months after the intervention. In the 0, 1, 3 months of intervention, the anthropometric parameters and body composition were measured by using bioelectrical impedance analysis method ( MC-980 MA PLUS, TANITA BIA Technology). In the 0, 1, 3 months of intervention, venous blood samples were taken from all subjects for measuring the marks of oxidative stress and inflammation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premenstrual Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

In the intervention phase of this study, 105 eligible participant were randomly divided into intervention (Grape King Hericium erinaceus Mycelium Capsules and Grape King Probiotic Capsules) and placebo groups (n=35/group). Both subjects and researchers were blind to the treatment assignment until the statistical analysis was completed.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Both subjects and researchers were blind to the treatment assignment until the statistical analysis was completed. All the subjects were randomly divided into placebo group and two intervention groups (i.e. supplementation with Grape King Hericium erinaceus Mycelium Capsules and Grape King Probiotic Capsules) by using Excel to generate random numbers.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hericium Erinaceus Mycelium

patients with premenstrual syndrome received supplementation of Hericium Erinaceus Mycelium capsules

Group Type EXPERIMENTAL

Hericium Erinaceus Mycelium

Intervention Type DIETARY_SUPPLEMENT

participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.

Probiotic

patients with premenstrual syndrome received supplementation of Probiotic capsules

Group Type EXPERIMENTAL

Probiotic

Intervention Type DIETARY_SUPPLEMENT

participants received two oral capsules containing Probiotic powder every day for the 3 months.

control

patients with premenstrual syndrome received supplementation of placebo capsules

Group Type PLACEBO_COMPARATOR

control

Intervention Type DIETARY_SUPPLEMENT

participants received two oral capsules containing control powder every day for the 3 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hericium Erinaceus Mycelium

participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.

Intervention Type DIETARY_SUPPLEMENT

Probiotic

participants received two oral capsules containing Probiotic powder every day for the 3 months.

Intervention Type DIETARY_SUPPLEMENT

control

participants received two oral capsules containing control powder every day for the 3 months.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women aged 20-45
2. The menstrual cycle is 21\~35 days/time
3. PMS diagnosed by an obstetrician
4. Willing to sign the subject's consent form

Exclusion Criteria

1. Those are with cancer, cardiovascular, kidney, liver, infectious and endocrine diseases, aw well as with depression and anxiety tendencies
2. Those have a surgery in the last 6 months
3. Those use of probiotics, estrogen and birth control pills
4. Body mass index \> 39 kg/m2, smoking, drinking
5. Death of a close relative and other stressful events within the last 6 months
Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chung Shan Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kai-Li Liu, PhD

Role: STUDY_CHAIR

Department of Nutrition, Chung Shan Medical University, Taichung, Taiwan

Man-Jung Hung, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Medicine, Chung Shan Medical University, Taichung, Taiwan

Yi-Chin Lin, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Nutrition, Chung Shan Medical University, Taichung, Taiwan

Pey-Ling Shieh Shieh, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Psychology, Chung Shan Medical University, Taichung, Taiwan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kai-Li Liu

Taichung, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

References

Explore related publications, articles, or registry entries linked to this study.

Duvan CI, Cumaoglu A, Turhan NO, Karasu C, Kafali H. Oxidant/antioxidant status in premenstrual syndrome. Arch Gynecol Obstet. 2011 Feb;283(2):299-304. doi: 10.1007/s00404-009-1347-y. Epub 2010 Jan 19.

Reference Type RESULT
PMID: 20084389 (View on PubMed)

Danis P, Drew A, Lingow S, Kurz S. Evidence-based tools for premenstrual disorders. J Fam Pract. 2020 Jan/Feb;69(1):E9-E17. No abstract available.

Reference Type RESULT
PMID: 32017837 (View on PubMed)

Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006 Jan;9(1):41-9. doi: 10.1007/s00737-005-0103-y. Epub 2005 Sep 20.

Reference Type RESULT
PMID: 16172836 (View on PubMed)

Sharifi-Rad J, Rodrigues CF, Stojanovic-Radic Z, Dimitrijevic M, Aleksic A, Neffe-Skocinska K, Zielinska D, Kolozyn-Krajewska D, Salehi B, Milton Prabu S, Schutz F, Docea AO, Martins N, Calina D. Probiotics: Versatile Bioactive Components in Promoting Human Health. Medicina (Kaunas). 2020 Aug 27;56(9):433. doi: 10.3390/medicina56090433.

Reference Type RESULT
PMID: 32867260 (View on PubMed)

Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010 Aug;31(4):231-7. doi: 10.2220/biomedres.31.231.

Reference Type RESULT
PMID: 20834180 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BR-CT004

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

CS2-20104

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Moxibustion for Primary Dysmenorrhea
NCT01972906 COMPLETED EARLY_PHASE1